CN108159021A - 一种载有促进骨形成蛋白及消除关节炎症状药物的双层复合缓释微球及其制备方法 - Google Patents
一种载有促进骨形成蛋白及消除关节炎症状药物的双层复合缓释微球及其制备方法 Download PDFInfo
- Publication number
- CN108159021A CN108159021A CN201810087592.3A CN201810087592A CN108159021A CN 108159021 A CN108159021 A CN 108159021A CN 201810087592 A CN201810087592 A CN 201810087592A CN 108159021 A CN108159021 A CN 108159021A
- Authority
- CN
- China
- Prior art keywords
- drug
- albumen
- layer compound
- preparation
- loaded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 229940079593 drug Drugs 0.000 title claims abstract description 49
- 239000004005 microsphere Substances 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 23
- 230000002917 arthritic effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000013268 sustained release Methods 0.000 title claims abstract description 19
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 19
- 230000001737 promoting effect Effects 0.000 title claims abstract description 18
- 208000024891 symptom Diseases 0.000 title claims abstract description 18
- 229920002567 Chondroitin Polymers 0.000 claims abstract description 13
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims abstract description 13
- 102000008186 Collagen Human genes 0.000 claims abstract description 12
- 108010035532 Collagen Proteins 0.000 claims abstract description 12
- 229920001436 collagen Polymers 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 12
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 12
- 239000000661 sodium alginate Substances 0.000 claims abstract description 12
- -1 Carboxymethyl sodium alginate Chemical compound 0.000 claims abstract description 6
- 229920001400 block copolymer Polymers 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000004626 polylactic acid Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 9
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 229960004275 glycolic acid Drugs 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 238000013019 agitation Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000010008 shearing Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 5
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 5
- 229920001610 polycaprolactone Polymers 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000003999 initiator Substances 0.000 claims description 3
- 229920001427 mPEG Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 235000019738 Limestone Nutrition 0.000 claims description 2
- DMGNFLJBACZMRM-UHFFFAOYSA-N O[P] Chemical compound O[P] DMGNFLJBACZMRM-UHFFFAOYSA-N 0.000 claims description 2
- 238000005253 cladding Methods 0.000 claims description 2
- 239000006028 limestone Substances 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims 8
- 150000002240 furans Chemical class 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 abstract description 6
- 210000000845 cartilage Anatomy 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000029087 digestion Effects 0.000 abstract description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract description 2
- 230000003139 buffering effect Effects 0.000 abstract description 2
- 239000011575 calcium Substances 0.000 abstract description 2
- 229910052791 calcium Inorganic materials 0.000 abstract description 2
- 230000008859 change Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 abstract description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 abstract 1
- 230000008542 thermal sensitivity Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810087592.3A CN108159021B (zh) | 2018-01-30 | 2018-01-30 | 一种载有促进骨形成蛋白及消除关节炎症状药物的双层复合缓释微球及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810087592.3A CN108159021B (zh) | 2018-01-30 | 2018-01-30 | 一种载有促进骨形成蛋白及消除关节炎症状药物的双层复合缓释微球及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108159021A true CN108159021A (zh) | 2018-06-15 |
CN108159021B CN108159021B (zh) | 2020-01-31 |
Family
ID=62512522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810087592.3A Expired - Fee Related CN108159021B (zh) | 2018-01-30 | 2018-01-30 | 一种载有促进骨形成蛋白及消除关节炎症状药物的双层复合缓释微球及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108159021B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113876724A (zh) * | 2021-12-07 | 2022-01-04 | 山东大学 | 一种负载帕瑞昔布、白介素-4和牛血清白蛋白用于骨关节炎治疗的双层微球及其制备方法 |
CN114702348A (zh) * | 2022-03-30 | 2022-07-05 | 开封青上化肥有限公司 | 一种能够提高种子发芽效率的海藻酸缓释肥料增效剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103371974A (zh) * | 2012-04-25 | 2013-10-30 | 中国科学院大连化学物理研究所 | 一种基于微流控技术制备的药物缓释聚合物微球及应用 |
CN104474552A (zh) * | 2014-11-24 | 2015-04-01 | 浙江大学 | 多功能多层微/纳米核壳结构的制备方法 |
-
2018
- 2018-01-30 CN CN201810087592.3A patent/CN108159021B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103371974A (zh) * | 2012-04-25 | 2013-10-30 | 中国科学院大连化学物理研究所 | 一种基于微流控技术制备的药物缓释聚合物微球及应用 |
CN104474552A (zh) * | 2014-11-24 | 2015-04-01 | 浙江大学 | 多功能多层微/纳米核壳结构的制备方法 |
Non-Patent Citations (1)
Title |
---|
ÖZGEERDEMLI等: "《Characteristics and release profiles of MPEG-PCL-MPEG microspheres containing immunoglobulin G》", 《COLLOIDS AND SURFACES B-BIOINTERFACES》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113876724A (zh) * | 2021-12-07 | 2022-01-04 | 山东大学 | 一种负载帕瑞昔布、白介素-4和牛血清白蛋白用于骨关节炎治疗的双层微球及其制备方法 |
CN113876724B (zh) * | 2021-12-07 | 2022-03-25 | 山东大学 | 一种负载帕瑞昔布、白介素-4和牛血清白蛋白用于骨关节炎治疗的双层微球及其制备方法 |
CN114702348A (zh) * | 2022-03-30 | 2022-07-05 | 开封青上化肥有限公司 | 一种能够提高种子发芽效率的海藻酸缓释肥料增效剂 |
Also Published As
Publication number | Publication date |
---|---|
CN108159021B (zh) | 2020-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6857214B2 (ja) | 関節の炎症およびそれに関連する疼痛を治療するための注射用持続放出組成物およびその使用方法 | |
JP2012511519A (ja) | 制御放出組成物 | |
CN106178129B (zh) | 载有bmp的明胶-海藻酸钙核壳结构缓释微球及其制备方法 | |
JP6893369B2 (ja) | 精神疾患または中枢神経系疾患治療用薬物伝達剤形 | |
CN106038478B (zh) | 一种葡萄糖敏感的多孔微球/聚合物复合凝胶及其制备方法和应用 | |
CN108186602A (zh) | 双层复合缓释微球在制备预防和治疗骨质疏松,关节炎和软骨恢复药物中的应用 | |
MX2014012208A (es) | Metodo y composiciones para preparar una microesfera de seda. | |
EP3865156B1 (en) | Sustained-release injection formulation comprising conjugate of poly-l-lactic acid filler and hyaluronic acid filler and bioactive materials, and preparation method thereof | |
CN102219938A (zh) | 一种疏水改性海藻酸钠的制备方法 | |
García-González et al. | Biomedical applications of polysaccharide and protein based aerogels | |
KR20170056573A (ko) | 치료제의 고도로 국소화된 방출을 위한 주입가능한 미립자 | |
CN108159021A (zh) | 一种载有促进骨形成蛋白及消除关节炎症状药物的双层复合缓释微球及其制备方法 | |
CN107233318A (zh) | 具有多级缓控释效果的羟基磷灰石载药微球的制备方法 | |
CN108912349A (zh) | 聚乳酸微球及其制备方法与在药物缓释中的应用 | |
CN105395487B (zh) | 一种制备可降解聚合物载药微球的双注射系统 | |
KR100720056B1 (ko) | 성장인자가 함유된 나노입자가 코팅된 마이크로스피어의제조 및 이의 신경분화로의 이용 방법 | |
CN112494728A (zh) | 微球基支架及其制备方法和应用 | |
KR20210121576A (ko) | 고분자 마이크로 입자, 고분자 마이크로 입자의 제조방법, 이를 포함하는 의료용 조성물, 미용 조성물, 의료 용품 및 미용 용품 | |
Han et al. | Supercritical CO 2-assisted fabrication of CM-PDA/SF/nHA nanofibrous scaffolds for bone regeneration and chemo-photothermal therapy against osteosarcoma | |
AU2022358001A1 (en) | Micro carrier, cell composite, and medical composition, cosmetic composition, medical articles and cosmetic articles using the same | |
CN110522949B (zh) | 一种载自然铜/骨碎补复方透钙磷石的制备方法 | |
Fang et al. | Preparation and biocompatibility evaluation of nanoscale Isoniazide-loaded mineralized collagen implants for tuberculous bone and joint repair | |
Yao et al. | Dual Factor-Loaded Artificial Periosteum Accelerates Bone Regeneration | |
Kamel et al. | Injectable hydrogel scaffolds composed of Nanocellulose derived from sugarcane bagasse and combined with calcium for Bone regeneration | |
CN108057031A (zh) | 预防手术后异位骨化的缓释吲哚美辛纳米颗粒及其注射剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Baolong Inventor after: Zhang Maoquan Inventor after: Zhang Mingzhu Inventor before: Zhang Mingzhu |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200106 Address after: Shibei District People's road 266033 Shandong city of Qingdao province No. 4 Applicant after: Liu Baolong Address before: 453000 No. 532, Cun Ying Cun, Da block Town, Fengquan District, Xinxiang, Henan Applicant before: Zhang Mingzhu Applicant before: HENAN RENFENJIUZHONG HEALTH MANAGEMENT CO.,LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200612 Address after: 266011 No.4 Renmin Road, Shibei District, Qingdao, Shandong Province Patentee after: TRADITIONAL CHINESE MEDICAL Co. Address before: Shibei District People's road 266033 Shandong city of Qingdao province No. 4 Patentee before: Liu Baolong |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200131 Termination date: 20220130 |
|
CF01 | Termination of patent right due to non-payment of annual fee |